Immunosuppression in IDDM. Rationale, risks, benefits, and strategies.
Mahon
J L
JL
University of Western Ontario, University Hospital, London, Canada.
Dupré
J
J
Stiller
C R
CR
Donner
A P
AP
D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects
D003524:Cyclosporins